KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Operating Expenses: 2009-2025

Historic Operating Expenses for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to $107.5 million.

  • Neogenomics' Operating Expenses rose 11.85% to $107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.1 million, marking a year-over-year increase of 15.12%. This contributed to the annual value of $382.2 million for FY2024, which is 8.48% up from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Operating Expenses is $107.5 million, which was down 13.95% from $124.9 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Operating Expenses peaked at $124.9 million during Q2 2025, and registered a low of $56.7 million during Q1 2021.
  • In the last 3 years, Neogenomics' Operating Expenses had a median value of $95.7 million in 2024 and averaged $97.1 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first spiked by 76.03% in 2021, then declined by 4.16% in 2022.
  • Neogenomics' Operating Expenses (Quarterly) stood at $86.8 million in 2021, then decreased by 4.16% to $83.2 million in 2022, then grew by 3.55% to $86.2 million in 2023, then grew by 11.02% to $95.7 million in 2024, then rose by 11.85% to $107.5 million in 2025.
  • Its Operating Expenses stands at $107.5 million for Q3 2025, versus $124.9 million for Q2 2025 and $101.1 million for Q1 2025.